The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysis
Abstract
Objective: To describe the relative risk for venous thrombosis (VT) associated with antiphos pholipid antibodies (aPL) in systemic lupus erythematosus (SLE). Design: Systematic review and meta-analysis of 26 articles that examined the association between aPL and VT in SLE. Setting: Mostly secondary and tertiary referral centres. Patients: 2249 patients with SLE, 1120 tested for LA (lupus anticoagulant) and 1563 tested for aCL (anticardiolipin antibodies). Main outcome measures: A summary of study characteristics and a critical appraisal of study quality were done. Two statistical combinations of 18 primary studies that examined the association of VT and LA and of 14 studies that examined the association of VT and aCL were performed to estimate the risk for VT associated with aPL. Results: The odds ratios of the risk of VT related to the LA summarized from 18 studies were 5.61 [95% CI; 3.80-8.27] overall, 6.32 [CI; 3.71-10.78] for deep venous thrombosis and pulmonary embolism, 11.6 [3.65--36.91] for recurrent venous thrombosis after the first event. The odds ratios of the risk of VT related to aCL summarized from 14 studies were 2.17 [95% CI; 1.51-3.11] overall, 2.50 [CI; 1.51-4.14] for deep venous thrombosis and pulmonary embolism, 3.91 [1.14- 13.38] for recurrent venous thrombosis after the first event. Conclusions: Patients with SLE and LA are at approximately six times greater risk for VT than patients without LA, whereas patients with SLE and aCL are approximately two times greater risk for VT than patients without aCL. We have identified important methodologic limitations and differences in study characteristics. Other risk factors for VT have not been thoroughly evaluated in these studies. Further studies are needed that provide an accurate estimate of the absolute risk for aPL related VT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Statistical Methods in Medical Research.
Armitage, P. (1972) · Biometrics · doi:10.2307/2556182 · Cited by 5,383
Alarcón-Segovia, D., Delezé, M., Oria, C. V., Sánchez‐Guerrero, J., Gómez-Pacheco, L., Cabiedes, J., Fernández, L. A. N., & de León, S. P. (1989) · Medicine · doi:10.1097/00005792-198911000-00003 · Cited by 635
Clinical Recommendations Using Levels of Evidence for Antithrombotic Agents
Cook, D. J., Guyatt, G. H., Laupacis, A., Sackett, D. L., & Goldberg, R. J. (1995) · CHEST Journal · doi:10.1378/chest.108.4_supplement.227s · Cited by 275
Horbach, D. A., van Oort, E., Donders, R. C. J. M., Derksen, R. H. W. M., & de Groot, P. G. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650686 · Cited by 246
Anglés‐Cano, E., Sultan, Y., & Clauvel, J. (1979) · PubMed · Cited by 219
Thrombosis in Systemic Lupus Erythematosus
Glueck, H. I. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360080059007 · Cited by 192
KALUNIAN, K. C., Middlekauff, H. R., Sayre, J. A., Ando, D. G., Mangotich, M., Hahn, B. H., & Peter, J. B. (1988) · The American Journal of Medicine · doi:10.1016/s0002-9343(88)80229-8 · Cited by 150
Anticardiolipin antibodies in patients with systemic lupus erythematosus
Sturfelt, G. K., Nived, O., Norberg, R., Thorstensson, R., & Krook, K. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300404 · Cited by 124
Worrall, J. G., SNAITH, M. L., Batchelor, J. R., et al. (1990) · QJM · doi:10.1093/oxfordjournals.qjmed.a068440 · Cited by 114
Platelet Function and Coagulation Profile in Lupus Erythematosus
Regan, M. G., LACKNER, H., & KARPATKIN, S. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-462 · Cited by 109
Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients
Manoussakis, M. N., Gharavi, A. E., Drosos, A. A., Kitridou, R. C., & Moutsopoulos, H. Μ. (1987) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(87)90073-0 · Cited by 103
Ginsberg, J. S., Demers, C., Brill-Edwards, P. A., et al. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80317-9 · Cited by 77
McHugh, N. J., Maymó, J., Skinner, R. P., et al. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.2.110 · Cited by 74
A Survey of Current Problems in Meta-Analysis
Hasselblad, V., Mosteller, F. C., Littenberg, B., Chalmers, T. C., Hunink, M. G. M., Turner, J. A., Morton, S. C., Diehr, P. H., Wong, J. B., & Powe, N. R. (1995) · Medical Care · doi:10.1097/00005650-199533020-00007 · Cited by 61
Renal vein thrombosis and inferior vena cava thrombosis in systemic lupus erythematosus
Mintz, G., Acevedo‐Vásquez, E. M., Gutiérrez‐Espinosa, G., et al. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270509 · Cited by 55
Ghirardello, A., Doria, A., Ruffatti, A., Rigoli, A. M., Vesco, P., Calligaro, A., & Gambari, P. F. (1994) · Annals of the Rheumatic Diseases · doi:10.1136/ard.53.2.140 · Cited by 48
LUPUS ANTICOAGULANT AS A PROGNOSTIC MARKER IN SYSTEMIC LUPUS ERYTHEMATOSUS
Jouhikainen, T., Stephansson, E., & Leirisalo‐Repo, M. (1993) · Lara D. Veeken · doi:10.1093/rheumatology/32.7.568 · Cited by 42
Haemostatic Abnormalities in Systemic Lupus Erythematosus
Gladman, D. D., UROWITS, M. B., Tozman, E. C., et al. (1983) · QJM · doi:10.1093/oxfordjournals.qjmed.a067771 · Cited by 38
Gharavi, A. E., & Wilson, W. (1996) · Lupus · doi:10.1177/096120339600500501 · Cited by 37
Circulating Anticoagulant in Systemic Lupus erythematosus: Clinical Manifestations
Pauzner, R., Rosner, E., & Many, A. (2009) · Acta Haematologica · doi:10.1159/000206028 · Cited by 34
The Prevalence and Clinical Associations of the Lupus Anticoagulant in Systemic Lupus Erythematosus
Derksen, R. H. W. M., Bouma, B. N., & Kater, L. (1987) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748709165272 · Cited by 32
Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus.
Jones, H. W., Ireland, R. M., Senaldi, G., et al. (1991) · Annals of the Rheumatic Diseases · doi:10.1136/ard.50.3.173 · Cited by 31
Wong, K.-L., Liu, H., Ho, K., et al. (1991) · PubMed · Cited by 31
Lupus Anticoagulant, Thrombosis and Thrombocytopenia in Systemic Lupus Erythematosus
Averbuch, M., Koifman, B., & Levo, Y. (1987) · The American Journal of the Medical Sciences · doi:10.1097/00000441-198701000-00002 · Cited by 28
Jouhikainen, T., Kekomäki, R., Leirisalo‐Repo, M., Bäcklund, T., & Myllylä, G. (1990) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1990.tb00385.x · Cited by 25
McHugh, N. J., Moye, D. A., James, I. E., Sampson, M., & Maddison, P. J. (1991) · Annals of the Rheumatic Diseases · doi:10.1136/ard.50.8.548 · Cited by 21
Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730.
Hilliquin, P., Natour, J., Aïssa, J., et al. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.2.140 · Cited by 11
Metz, D., Jolly, D., Graciet-Richard, J., et al. (1994) · PubMed · Cited by 7
Ferro, D., Saliola, M., Quintarelli, C., et al. (1990) · Thrombosis Research · doi:10.1016/0049-3848(90)90419-d · Cited by 5
Research works printed but not linked: 9
- Chalmers I, 1995, Systematic Reviews
- Bowie Ejw, 1963, Clin Med, 62, 416
- Angles-Cano E., 1979, J Lab Clin Med, 94, 312
- Gladman DD, 1983, Q J Med, 52, 424
- Petri M., 1987, Arch Intern Med, 106, 524
- Rowell NR, 1989, Acta Derm Venereol (Stockh), 69, 111
- Worrall JG, 1990, Q J Med, 74, 319
- Wong KL, 1991, J Rheumatol, 18, 1187
- Metz D., 1994, Presse Med, 23, 1797
Cited by
Sorted by citations
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,524
“It was also shown (17, 18, 19, 20) that discontinuation of anticoagulants seems to be associated with an increased risk of thrombosis (up to 70 %), and even death, especially in the first six months : anticoagulation should therefore be long term, if not lifelong.”
BackgroundU.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Combes, V., Simon, A.-C., Grau, G. E., Arnoux, D., Camoin‐Jau, L., Sabatier, F., Mutin, M., Sanmarco, M., Sampol, J., & Dignat‐George, F. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4985 · Cited by 731
“This coagulation abnormality is well recognized to be strongly associated with a thrombotic tendency (31, 32).”
BackgroundThe Pathogenesis of the Antiphospholipid Syndrome
Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 687
Metadata
- Authors
- Wahl, D., Guillemin, F., de Maistre, E., Perret, C., Lecompte, T., & Thibaut, G.
- Affiliations
- Service de Medicine H., Nancy University Hospital, Nancy, France
- Université de Lorraine (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 1997-06
- Volume
- 6
- Issue
- 5
- Pages
- 467-473
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2080975717
- Semantic Scholar
- c31dc580c59a1ad743aa46934306445622100694
- Cited by
- 285
- References
- 29
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 11 · 2023: 8 · 2022: 6 · 2021: 10 · 2020: 10 · 2019: 9 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 5 · 2013: 11 · 2012: 5
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- venous thrombosis, antiphospholipid antibodies, systemic lupus erythematosus, lupus anticoagulant, anticardiolipin antibodies, deep vein thrombosis, pulmonary embolism, recurrent venous thrombosis, thrombosis risk
- MeSH terms
- Autoimmune Diseases, Disease Susceptibility, Epidemiologic Methods, Humans, Lupus Erythematosus, Systemic, Risk, Thrombophlebitis, Comorbidity, Odds Ratio, Single-Blind Method, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Antibodies, Anticardiolipin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
